Pesquisas alternativas:
mtor complex » mediator complex (Expandir a Pesquisa)
complex can » complex case (Expandir a Pesquisa), complex care (Expandir a Pesquisa), complex cell (Expandir a Pesquisa)
bad company » a company (Expandir a Pesquisa), lncd company (Expandir a Pesquisa), good company (Expandir a Pesquisa)
la compra » la comarca (Expandir a Pesquisa), de compra (Expandir a Pesquisa), la comida (Expandir a Pesquisa)
compra en » compra e (Expandir a Pesquisa), compra de (Expandir a Pesquisa), compra do (Expandir a Pesquisa)
company a » company _ (Expandir a Pesquisa)
en newly » men newly (Expandir a Pesquisa), ten newly (Expandir a Pesquisa), when newly (Expandir a Pesquisa)
5p mtor » p mtor (Expandir a Pesquisa)
3 bad » 3 band (Expandir a Pesquisa), _ bad (Expandir a Pesquisa), a bad (Expandir a Pesquisa)
a non » _ non (Expandir a Pesquisa)
j la » j a (Expandir a Pesquisa), j l (Expandir a Pesquisa), j da (Expandir a Pesquisa)
mtor complex » mediator complex (Expandir a Pesquisa)
complex can » complex case (Expandir a Pesquisa), complex care (Expandir a Pesquisa), complex cell (Expandir a Pesquisa)
bad company » a company (Expandir a Pesquisa), lncd company (Expandir a Pesquisa), good company (Expandir a Pesquisa)
la compra » la comarca (Expandir a Pesquisa), de compra (Expandir a Pesquisa), la comida (Expandir a Pesquisa)
compra en » compra e (Expandir a Pesquisa), compra de (Expandir a Pesquisa), compra do (Expandir a Pesquisa)
company a » company _ (Expandir a Pesquisa)
en newly » men newly (Expandir a Pesquisa), ten newly (Expandir a Pesquisa), when newly (Expandir a Pesquisa)
5p mtor » p mtor (Expandir a Pesquisa)
3 bad » 3 band (Expandir a Pesquisa), _ bad (Expandir a Pesquisa), a bad (Expandir a Pesquisa)
a non » _ non (Expandir a Pesquisa)
j la » j a (Expandir a Pesquisa), j l (Expandir a Pesquisa), j da (Expandir a Pesquisa)
1
Por J. Chris Kingswood, Elena Belousova, Mirjana P. Benedik, Tom Carter, Vincent Cottin, Paolo Curatolo, Maria Dahlin, Lisa D'Amato, Guillaume Beaure d'Augères, Petrus J. de Vries, José C. Ferreira, Martha Feucht, Carla Fladrowski, Carla Fladrowski, Christoph Hertzberg, Sergiusz Jozwiak, Sergiusz Jozwiak, John A. Lawson, Alfons Macaya, Ruben Marques, Ruben Marques, Rima Nabbout, Finbar O'Callaghan, Jiong Qin, Valentin Sander, Seema Shah, Yukitoshi Takahashi, Renaud Touraine, Sotiris Youroukos, Bernard Zonnenberg, Anna C. Jansen, Matthias Sauter
Publicado em 2020-09-01
Assuntos:
“...mTOR...”Publicado em 2020-09-01
Obter o texto integral
Artigo
2
Por Veronika Palušová, Tereza Renzová, Amandine Verlande, Tereza Vaclová, Michaela Medková, Linda Cetlová, Miroslava Sedláčková, Hana Hříbková, Iva Slaninová, Miriama Krutá, Vladimír Rotrekl, Hana Uhlířová, Aneta Křížová, Radim Chmelík, Pavel Veselý, Michaela Krafčíková, Lukáš Trantírek, Kay Oliver Schink, Stjepan Uldrijan
Publicado em 2020-06-01
“... complex protein p18/LAMTOR1 at contact sites of large vesicles and delocalization of mTOR from...”Publicado em 2020-06-01
Obter o texto integral
Artigo
3
Por Wang, Yinfang, Wan, Xiaohong, Hao, Yilong, Zhao, Yuanyuan, Du, Lanlan, Huang, Yitong, Liu, Zongjun, Wang, Ying, Wang, Nanping, Zhang, Peng
Publicado no Cell Commun Signal (2019)
“... receptor (INSR) and potentitated insulin-induced phosphorylation of mTOR and AKT partly via miR-205-5p...”Publicado no Cell Commun Signal (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Bannaga, Ayman, Kelman, Lawrence, O'Connor, Michelle, Pitchford, Claire, Walters, Julian R F, Arasaradnam, Ramesh P
Publicado no BMJ Open Gastroenterol (2017)
“... responses were analysed. 91% of the respondents reported a diagnosis of BAD. 58% of total respondents...”Publicado no BMJ Open Gastroenterol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
“... starting before 50 years of age and lasting for 3–36 months, were used. A bad functional outcome at 24...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
7
“... in mammalian target of rapamycin sensitive complex 1 (mTORC1)-positive cells (70.80 ± 2.41 vs. 112.30 ± 5.66, F...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
“...% of the students had never received any kind of gift from a drug company or participated in any drug company...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Van Der Steen, Nele, Deben, Christophe, Deschoolmeester, Vanessa, Wouters, An, Lardon, Filip, Rolfo, Christian, Germonpré, Paul, Giovannetti, Elisa, Peters, Godefridus J, Pauwels, Patrick
Publicado no World J Clin Oncol (2016)
“... in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor...”Publicado no World J Clin Oncol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Screening a large pediatric cohort with GH deficiency for mutations in genes regulating pituitary...
Por Werner F. Blum, Jürgen Klammt, Serge Amselem, Heike M. Pfäffle, Marie Legendre, Marie-Laure Sobrier, Marie-Pierre Luton, Christopher J. Child, Christine Jones, Alan G. Zimmermann, Charmian A. Quigley, Gordon B. Cutler, Jr, Cheri L. Deal, Jan Lebl, Ron G. Rosenfeld, John S. Parks, Roland W. Pfäffle
Publicado em 2018-10-01
“... they were only moderately diminished (3-6 μg/L). Two patients with a GH1 mutation developed TSH deficiency...”Publicado em 2018-10-01
Obter o texto integral
Artigo
11
Por Guthrie, Bruce, Donnan, Peter T, Murphy, Douglas J, Makubate, Boikanyo, Dreischulte, Tobias
Publicado no BMJ Open (2015)
“... if it is largely driven by individuals (a ‘bad apple’ problem) or by practices having higher or lower risk...”Publicado no BMJ Open (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Thamirys Sousa Correia, Wenner Glaucio Lopes Lucena
Publicado no RAUSP Management Journal (2020)
“... for the methodology, data were collected from companies that traded shares in Brasil, Bolsa e Balcão (B3) through...”Publicado no RAUSP Management Journal (2020)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Signaling Networks of Activated Oncogenic and Altered Tumor Suppressor Genes in Head and Neck Cancer
Por Yan, Bin, Broek, Robert Vander, Saleh, Anthony D, Mehta, Arpita, Van Waes, Carter, Chen, Zhong
Publicado no J Carcinog Mutagen (2013)
“..., including TP53/p63/p73 family members, IL-1/TNF-β/NF-κB, PI3K/AKT/mTOR, IL-6/IL-6R/JAK/STAT3, EGFR/MAPK/AP1...”Publicado no J Carcinog Mutagen (2013)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por Sankaranarayanan, Rajiv, Kirkwood, Graeme, Visweswariah, Rajaverma, Fox, David J.
Publicado no Curr Cardiol Rev (2015)
“... risk from AF is due to the “bad company it keeps” i.e. the associated co-morbidities rather than AF...”Publicado no Curr Cardiol Rev (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Romero-Aroca, Pedro, de la Riva-Fernandez, Sofia, Valls-Mateu, Aida, Sagarra-Alamo, Ramon, Moreno-Ribas, Antonio, Soler, Nuria
Publicado no Br J Ophthalmol (2016)
“... yearly mean value of 2.19±0.18% (2%–2.49%). A clear increase was observed in the last 3 years, any DR...”Publicado no Br J Ophthalmol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
“... in three counties in Germany during a 3-month study period (N=1017). Cross-sectional data on the resident...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Jayawardana Naveen, Kulatunga Supun, Lamabadusuriya Dilusha A, Perera Yashasvi S, Ranasinghe Priyanga, Rajapakse Senaka, Katulanda Prasad
Publicado em 2011-04-01
“...<p>Abstract</p> <p>Background</p> <p>Complaints of arm, neck and/or shoulders (CANS) affects...”Publicado em 2011-04-01
Obter o texto integral
Artigo
18
Por Ranasinghe, Priyanga, Perera, Yashasvi S, Lamabadusuriya, Dilusha A, Kulatunga, Supun, Jayawardana, Naveen, Rajapakse, Senaka, Katulanda, Prasad
Publicado em 2011
“... ± 9.5 years. One-year prevalence of CANS was 63.6% (mild-53.7% and severe-10%). The highest incidences...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
20